The study by Beier et al provided the important evidence that CD133+ cancer stem cells display resistance to conventional chemotherapy drugs; the CD133+ levels of recurrent tumors are higher than those of primary tumors in patients with glioblastoma multiforme (19). Here, PROM1 is linked to glioblastoma.